Literature DB >> 498714

Amantadine kinetics in healthy young subjects after long-term dosing.

F Y Aoki, D S Sitar, R I Ogilvie.   

Abstract

We investigated the disposition of amantadine in 13 healthy, young adults after long-term dosage. Doses of 25, 100, or 150 mg, randomly allocated, were taken at 12-hr intervals in syrup for 31 doses. A 1-compartment open model and complete bioavailability were assumed. Absorption rate was variable with peak concentrations in plasma occurring at 1 to 12 hr. Since the calculated area under the plasma concentration against time curve was proprotional to it, relative bioavailability was independent of dose at steady state. As the dose increased, the apparent volume of distribution decreased. Intra- and intersubject variations in trough plasma drug concentrations at steady state were less than triple for equivalent doses. Elimination of drug from plasma was consistent with a first-order process. Plasma half-lifes (t1/2s) ranged from 10.2 to 31.4 hr and were independent of dose or creatinine clearance. The ratio of renal drug clearance to creatinine clearance ranged from 1.26 to 14.97, suggesting substantial renal tubular secretion. The median ratio of plasma drug clearance to renal drug clearance approached unity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498714     DOI: 10.1002/cpt1979266729

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

2.  Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.

Authors:  M Brenner; A Haass; P Jacobi; K Schimrigk
Journal:  J Neurol       Date:  1989-03       Impact factor: 4.849

3.  Multiple-dose pharmacokinetics of rimantadine in elderly adults.

Authors:  R L Tominack; R J Wills; L E Gustavson; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

4.  Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults.

Authors:  F G Hayden; A Minocha; D A Spyker; H E Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

6.  Amantadine: a review of use in child and adolescent psychiatry.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2013-02

7.  Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.

Authors:  F G Hayden; J M Gwaltney; R L Van de Castle; K F Adams; B Giordani
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

8.  Plaque inhibition assay for drug susceptibility testing of influenza viruses.

Authors:  F G Hayden; K M Cote; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

9.  Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.

Authors:  Robert A Hauser; Rajesh Pahwa; William A Wargin; Cindy J Souza-Prien; Natalie McClure; Reed Johnson; Jack T Nguyen; Rajiv Patni; Gregory T Went
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447

10.  Chapter 7 Orthomyxovirus infections.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.